Resolution Therapeutics Will Present Liver Trial Data

The company is scheduled to share new findings on its regenerative cell therapy in Denver this November.

Updated on Oct. 6, 2026 in Biotech

Bold vector editorial illustration showing intricate, repeating cellular fiber structures in teal and sage, representing regenerative medical research. — Resolution Therapeutics will present interim Phase I/II data on its regenerative liver cell therapy, RTX001, at the American Association for the Study of Liver Diseases conference in Denver. AI Illustration. Upload story photo >

Live Poll

Do you believe medical research is currently improving treatment options for patients with chronic diseases?

Resolution Therapeutics will present interim Phase I/II EMERALD trial data at the American Association for the Study of Liver Diseases conference on November 8, 2026. The study evaluates the safety and efficacy of the cell therapy RTX001 in patients who have recovered from recent hepatic decompensation.

Why it matters

The trial aims to address the significant mortality and limited transplant options associated with end-stage liver disease. By targeting inflammation and fibrosis at the microenvironment level, the company seeks to leverage its regenerative platform to trigger natural repair processes.

The EMERALD trial investigates the safety and tolerability of RTX001, which uses a proprietary platform to develop macrophages with pro-regenerative properties. Patients in this study are currently monitored for outcomes following recent hepatic decompensation.

The players

Resolution Therapeutics

This biotechnology firm based in Edinburgh and London specializes in developing macrophage cell therapies for inflammatory and fibrotic diseases.

Dr. Lara Campana

A researcher associated with the company who is scheduled to present preclinical findings on regenerative macrophage therapy.

The details

Resolution Therapeutics is also set to present preclinical data regarding intravenous Regenerative Macrophage Therapy on November 7, 2026. This therapy is designed to manage the severe health outcomes of decompensation, which currently carries a 37% mortality rate within two years.

November 7, 2026, 08:30 MST: Preclinical RMT data presentation.
November 8, 2026, 13:00 MST: Presentation of interim EMERALD trial results.
November 5-9, 2026: The American Association for the Study of Liver Diseases conference in Denver.

The Tech Race

This development represents a broader industry shift toward using specialized cellular platforms to replace traditional, often palliative care for chronic organ failure. It positions the company as a competitor in the growing regenerative medicine sector by targeting underlying tissue fibrosis.

The trial results may eventually change standard treatment protocols for patients suffering from end-stage liver disease who currently have limited options. Success in these studies could influence the future availability of regenerative therapies for the broader patient population.

The takeaway

Advancements in macrophage-based therapy aim to reduce the reliance on liver transplants by initiating internal organ repair. These upcoming clinical presentations provide necessary insight into the feasibility of addressing fibrosis before it becomes irreversible.